LCMV-GP Pseudotyped VSV Vectors for Solid Tumor Gene Therapy

The patent applies local quality by engineering the viral vector to have different properties in different locations: the VSV-LCMV-GP pseudotype is designed to specifically recognize and bind to receptors expressed on tumor cells (local targeting), while avoiding binding to healthy cells. This is achieved by using the LCMV glycoprotein GP which has selective affinity for tumor cell surfaces, thereby concentrating the therapeutic effect locally at the tumor site while sparing healthy tissue.

The patent employs parameter changes by modifying the viral vector's genetic and structural parameters to achieve selective tumor targeting. Specifically, the vector uses mutations in the VSV polymerase gene (creating a temperature-sensitive mutant that replicates only at 37°C in tumor tissue) and pseudotyping with LCMV-GP to alter its tropism. These parameter changes enable the vector to differentiate between tumor and healthy cells based on temperature and receptor expression differences.

The patent applies preliminary action by first establishing efficient packaging cell lines that are pre-engineered to produce high titers of the VSV-LCMV-GP pseudyped vectors. These packaging cells contain all necessary viral components except the therapeutic gene, allowing them to efficiently package and release large amounts of functional vectors. This preliminary preparation ensures that when the vectors are administered, there is sufficient quantity and quality to achieve effective gene transfer and treatment.

The patent uses an intermediary approach by employing packaging cells as a mediator between the vector design and the final therapeutic application. These intermediate packaging cells serve as factories that produce the actual therapeutic vectors, allowing optimization of vector production separately from the therapeutic mechanism. This intermediary system enables high-efficiency gene transfer by using professionally competent packaging cells that have been optimized for vector production.

The patent converts potential harm into benefit by using the naturally cytopathic properties of VSV against tumor cells. The vesicular stomatitis virus inherently causes cell lysis and death, which is harmful to healthy cells but beneficial for tumor destruction. By engineering temperature-sensitive mutants and selective pseudotyping, the patent redirects this harmful cytopathic effect specifically toward tumor cells, converting a potential safety issue into a therapeutic mechanism that destroys tumor cells while sparing healthy tissue.

The patent applies segmentation by separating the viral vector into multiple functional components distributed across different elements: the VSV backbone provides replication and cytopathic effects, the LCMV-GP pseudotype provides selective targeting, temperature-sensitive mutations provide spatial control, and separate packaging cells provide production capability. This segmentation allows each component to be optimized independently for its specific function while minimizing overall toxicity through controlled interaction of the separated elements.